HONG KONG, Dec. 15, 2025 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3 E Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider with the inspiration to become a next-generation artificial intelligence (“AI”) infrastructure solutions provider, today announced the execution of a Master Services Agreement (the “Agreement”) with Orka Technologies Oy ("Orka Technologies"), a Finnish company, to jointly develop an AI data ...

TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Aecon Group Inc. (TSX: ARE) (“Aecon”) announced today that the Board of Directors approved its next quarterly dividend of 19 cents per share. The dividend will be paid on January 5, 2026 to shareholders of record as of December 24, 2025. About Aecon Aecon Group Inc. (TSX: ARE) is a North American construction and infrastructure development company with global experience. Aecon delivers integrated solutions to private and public-sector clients through its Constructi ...

THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026 PHILADELPHIA, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that its Phase 2 clinical study ...

Core Insights - Dyadic Applied BioSolutions has entered into a commercial agreement with Opes Diagnostics Limited to support the launch of its recombinant proteins for serum-free cell culture media applications in various markets [1][2][4] Company Overview - Dyadic is a global biotechnology company that produces precision-engineered, animal-free proteins and enzymes for life science, food & nutrition, and bioindustrial markets [1][5] - The company utilizes proprietary microbial expression platforms to manufacture recombinant proteins, which are designed to enable customers to develop more efficient and sustainable products [5] Partnership Details - Under the agreement, Opes will leverage its existing relationships to identify potential customers primarily in Europe, Israel, and Asia, facilitating market entry for Dyadic's recombinant protein portfolio [2][3] - The collaboration aims to enhance the penetration of Dyadic's products in industries such as research, diagnostics, cultured meat, and biomanufacturing [3][4] Market Strategy - The partnership is expected to drive the adoption of Dyadic's cell culture media products into expanding markets, transitioning the company from development activities to broader commercial engagement [4]

Financial Calendar - A.P. Møller - Mærsk A/S plans to publish its Annual Report for 2025 on 5 February 2026 [3] - The Interim Report for the 1st quarter is scheduled for 7 May 2026 [3] - The Interim Report for the 2nd quarter is set for 6 August 2026 [3] - The Interim Report for the 3rd quarter will be released on 5 November 2026 [3] Annual General Meeting - The Annual General Meeting is expected to be held on Wednesday, 25 March 2026 [2] - Any issues for the agenda must be received by the Company no later than 10 February 2026 [2]

Core Insights - Orelabrutinib is the first BTK inhibitor to show significant clinical activity in a Phase 2 clinical trial for Systemic Lupus Erythematosus (SLE) [1] - Zenas BioPharma has acquired exclusive rights to develop, manufacture, and commercialize orelabrutinib for Multiple Sclerosis (MS) globally, and for non-oncology fields outside Greater China and Southeast Asia [1][5] Clinical Trial Results - In the Phase 2b study, 187 patients were randomized into three groups: orelabrutinib 75 mg once-daily, orelabrutinib 50 mg once-daily, and placebo [2] - The primary endpoint, SLE Response Index-4 (SRI-4) response rate at week 48, was met with the 75 mg group showing a response rate of 57.1% compared to 34.4% for placebo (p < 0.05) [2] - Secondary endpoints, including SRI-6 and British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response rates, were also significantly higher in the 75 mg group compared to placebo (p < 0.05) [3] Safety and Tolerability - Orelabrutinib was well tolerated, exhibiting a safety profile consistent with BTK inhibition and the disease biology of SLE [3] Development Pipeline - Zenas is advancing orelabrutinib into a Phase 3 trial for Primary Progressive MS (PPMS) and plans to initiate a Phase 3 trial for Secondary Progressive MS (SPMS) in Q1 2026 [6] - Orelabrutinib is already approved for B cell malignancies in mainland China and Singapore, marketed by InnoCare [6] Company Overview - Zenas BioPharma is a clinical-stage global biopharmaceutical company focused on developing transformative therapies for autoimmune diseases [7] - The company is advancing two late-stage molecules: obexelimab and orelabrutinib, with obexelimab being a bifunctional monoclonal antibody targeting CD19 and FcγRIIb [7][8]

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully completed its latest production cycle, yielding over one million BAM-1 Alpha hybrid eggs, which will be released in the upcoming quarter for recombinant spider silk production [1][2]. Production and Technology Advancements - The BAM-1 Alpha line has shown greater uniformity and resiliency throughout the production process, leading to improved throughput, consistency, and reliability for the company's spider silk manufacturing platform [2][3]. - The production capacity increase from BAM-1 Alpha is driving the company's expansion initiatives in Southeast Asia [3]. Strategic Outlook - The company has developed an aggressive production schedule for the next six months based on the successful results from BAM-1 Alpha and is already implementing this plan [4]. - The reliability and robustness of the BAM-1 Alpha line are enabling the company to confidently advance its commercial rollout [4].

Core Points - XPO, Inc. announced that Brad Jacobs will step down as Executive Chairman effective December 31, 2025, transitioning to a Special Advisor role until June 30, 2026, while Mario Harik will become Chairman of the Board and continue as CEO [1] - Harik's appointment as Chairman emphasizes the company's commitment to strategic continuity and long-term value creation for stakeholders [1] - Jacobs praised Harik's exceptional performance in various roles and expressed confidence in the company's future under his leadership [2] Company Overview - XPO, Inc. is a leader in asset-based less-than-truckload (LTL) freight transportation in North America, moving 17 billion pounds of freight annually [3] - The company serves 55,000 customers through 605 locations and employs 38,000 people across North America and Europe [3] - XPO is headquartered in Greenwich, Connecticut, USA [3]

Core Insights - Bitdeer Technologies Group reported significant growth in Bitcoin production and self-mining hashrate, with a year-over-year increase of 251% in Bitcoin mined, totaling 526 Bitcoins in November 2025 [5][7] - The company is actively scaling its AI cloud services, achieving an Annual Recurring Revenue (ARR) of approximately $10 million, up from $8 million in October 2025, indicating strong market demand [5][6] Operational Update - The total proprietary hash rate deployed increased to 47.3 EH/s in November 2025, up from 41.3 EH/s in October 2025 [3][7] - The cumulative deployment of SEALMINER A2 reached 34.3 EH/s, while SEALMINER A3 saw a deployment of 0.6 EH/s [3] - The total hash rate under management as of November 30, 2025, was 60.3 EH/s, compared to 55.5 EH/s in October 2025 [7] SEALMINER R&D - The SEAL04-1 chip demonstrated improved power efficiency of approximately 6-7 J/TH, with mass production targeted for Q1 2026 [6] - The company plans to continue deploying SEALMINER mining rigs while retiring older-generation third-party rigs [5] Infrastructure and Operations - Bitdeer has secured a 2 MW AI data center lease in Malaysia, expected to launch by year-end 2025 [6] - The company is actively evaluating U.S. data center leasing opportunities to enhance its AI cloud services, with several projects in various stages of development [10][13] - Total global electrical capacity stands at 2,992 MW, with ongoing projects expected to increase capacity further [13][14] Management Commentary - The Chief Business Officer highlighted expectations to achieve a self-mining hashrate milestone of 50 EH/s by year-end 2025, with continued growth planned through 2026 [7] - The company is focused on scaling its GPU infrastructure to meet the growing demand for high-performance computing [7]

Core Insights - FibroGen's roxadustat has received Orphan Drug Designation from the FDA for treating myelodysplastic syndromes (MDS), indicating a significant treatment gap in this area [2][3] - The company plans to submit the Phase 3 protocol for roxadustat in the fourth quarter of 2025 [1][2] Company Overview - FibroGen, Inc. is a biopharmaceutical company focused on developing novel therapies for cancer and anemia [7][8] - Roxadustat is already approved in Europe, Japan, and other countries for treating anemia in chronic kidney disease (CKD) patients [6][8] Treatment Landscape - Approximately 58,000 patients in the U.S. are diagnosed with lower-risk MDS (LR-MDS), with 85% suffering from anemia [2] - Current first-line treatments achieve transfusion independence in less than 50% of patients, highlighting the need for more effective options [2][4] - Roxadustat has shown benefits in transfusion independence compared to placebo in patients with high transfusion burden [2][4] Drug Mechanism - Roxadustat is an oral medication that promotes red blood cell production by increasing endogenous erythropoietin, improving iron absorption, and downregulating hepcidin [5] Market Potential - The FDA's Orphan Drug Designation provides benefits such as market exclusivity for seven years post-approval, which could enhance the commercial prospects for roxadustat [3]